New long-term data will further substantiate potential of gefurulimab as once-weekly subcutaneous self-administered treatment for adults with gMG Additional data will showcase commitment to advancing ...

Alexion, AstraZeneca Rare Disease, will deliver 16 presentations, including three oral presentations, across hypophosphatasia (HPP), chronic hypoparathyroidism (HypoPT) and early research at the ...

An experimental drug from AstraZeneca succeeded in a late-stage trial in an autoimmune condition called generalized myasthenia gravis, positioning the company to grow a business it inherited when ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

WILMINGTON, Del.--(BUSINESS WIRE)--Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine ...

AstraZeneca ( AZN ), a biopharmaceutical company, said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Enhertu for an additional early ...

“We had three very unique patients—three different walks of life, three different communities, from various states—yet their journey led them all to a very common place,” Tamar Thompson, Alexion's ...

Pangaea Data, a company focused on detecting hard-to-diagnose diseases in patients, is partnering with Alexion, a subsidiary of AstraZeneca focused on treating rare diseases, to co-develop, clinically ...

The book focuses on providing kids and their caregivers with information in four key areas: how aHUS affects the kidneys, its impact on daily life, details of the patient journey, and tips for dealing ...

LogicBio acquisition to build on current collaborations and advancements in genomic medicine LEXINGTON, Mass., Oct. 3, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (TXMD) (NASDAQ: LOGC), a ...

(RTTNews) - Wednesday, Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, has entered into a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for Koselugo for the treatment ...